CEMIP-话题@MedSci

#CEMIP#

10篇内容 | 769人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1782818, encodeId=d12d1e82818e1, content=<a href='/topic/show?id=99c54482b2' target=_blank style='color:#2F92EE;'>#CEMIP#</a>, objectTitle=NEJM：Cemiplimab用于II 至 IV 期可切除的皮肤鳞状细胞癌的新辅助治疗, objectType=article, longId=739152, objectId=0ec4e39152ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ec4e39152ac, replyNumber=0, likeNumber=114, createdTime=2023-05-02, rootId=0, userName=zlawrance, userId=f5e185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ec4e39152ac, moduleTitle=NEJM：Cemiplimab用于II 至 IV 期可切除的皮肤鳞状细胞癌的新辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ec4e39152ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1782817, encodeId=6ecc1e82817a7, content=<a href='/topic/show?id=99c54482b2' target=_blank style='color:#2F92EE;'>#CEMIP#</a>, objectTitle=研究性癌症疫苗BNT116联合Libtayo (cemiplimab) 治疗非小细胞肺癌, objectType=article, longId=300372, objectId=d6ea3003e273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6ea3003e273, replyNumber=0, likeNumber=91, createdTime=2022-04-08, rootId=0, userName=zlawrance, userId=f5e185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6ea3003e273, moduleTitle=研究性癌症疫苗BNT116联合Libtayo (cemiplimab) 治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6ea3003e273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1782816, encodeId=d6ba1e82816de, content=<a href='/topic/show?id=99c54482b2' target=_blank style='color:#2F92EE;'>#CEMIP#</a>, objectTitle=NEJM：采用Cemiplimab治疗复发性宫颈癌, objectType=article, longId=295537, objectId=c58b29553e6f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c58b29553e6f, replyNumber=0, likeNumber=74, createdTime=2022-11-11, rootId=0, userName=zlawrance, userId=f5e185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c58b29553e6f, moduleTitle=NEJM：采用Cemiplimab治疗复发性宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c58b29553e6f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1782815, encodeId=1d0e1e8281564, content=<a href='/topic/show?id=99c54482b2' target=_blank style='color:#2F92EE;'>#CEMIP#</a>, objectTitle=Eur J Cancer：Cemiplimab治疗局部晚期/转移性皮肤鳞状细胞癌的真实数据, objectType=article, longId=217450, objectId=f9a121e450ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9a121e450ea, replyNumber=0, likeNumber=85, createdTime=2022-01-02, rootId=0, userName=zlawrance, userId=f5e185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9a121e450ea, moduleTitle=Eur J Cancer：Cemiplimab治疗局部晚期/转移性皮肤鳞状细胞癌的真实数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9a121e450ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1782814, encodeId=30e31e8281417, content=<a href='/topic/show?id=99c54482b2' target=_blank style='color:#2F92EE;'>#CEMIP#</a>, objectTitle=Lancet oncol：Cemiplimab在局部晚期基底细胞癌中的抗肿瘤活性令人可期, objectType=article, longId=211377, objectId=f1712113e75f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1712113e75f, replyNumber=0, likeNumber=71, createdTime=2022-04-21, rootId=0, userName=zlawrance, userId=f5e185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1712113e75f, moduleTitle=Lancet oncol：Cemiplimab在局部晚期基底细胞癌中的抗肿瘤活性令人可期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1712113e75f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1782813, encodeId=15e41e8281353, content=<a href='/topic/show?id=99c54482b2' target=_blank style='color:#2F92EE;'>#CEMIP#</a>, objectTitle=Lancet Oncol：Cemiplimab治疗局部晚期皮肤鳞状细胞癌, objectType=article, longId=186331, objectId=e0e618633192, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0e618633192, replyNumber=0, likeNumber=76, createdTime=2020-05-18, rootId=0, userName=zlawrance, userId=f5e185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0e618633192, moduleTitle=Lancet Oncol：Cemiplimab治疗局部晚期皮肤鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0e618633192)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1782812, encodeId=27e31e82812a6, content=<a href='/topic/show?id=99c54482b2' target=_blank style='color:#2F92EE;'>#CEMIP#</a>, objectTitle=Nat cell biol:脑转移“助推剂”CEMIP，有望成为新的生物标志物, objectType=article, longId=182559, objectId=5f8618255995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f8618255995, replyNumber=0, likeNumber=81, createdTime=2020-02-22, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f8618255995, moduleTitle=Nat cell biol:脑转移“助推剂”CEMIP，有望成为新的生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f8618255995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1782811, encodeId=efde1e828117b, content=<a href='/topic/show?id=99c54482b2' target=_blank style='color:#2F92EE;'>#CEMIP#</a>, objectTitle=Inovio的INO-5401联合PD-1单抗cemiplimab治疗多形胶质母细胞瘤的2期研究，显示出80％的6个月无进展生存率, objectType=article, longId=182511, objectId=04741825119a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04741825119a, replyNumber=0, likeNumber=83, createdTime=2020-06-05, rootId=0, userName=zlawrance, userId=f5e185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04741825119a, moduleTitle=Inovio的INO-5401联合PD-1单抗cemiplimab治疗多形胶质母细胞瘤的2期研究，显示出80％的6个月无进展生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04741825119a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1782810, encodeId=836d1e8281014, content=<a href='/topic/show?id=99c54482b2' target=_blank style='color:#2F92EE;'>#CEMIP#</a>, objectTitle=NEJM：Cemiplimab用于晚期皮肤鳞状细胞癌, objectType=article, longId=140054, objectId=3805140054f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3805140054f9, replyNumber=0, likeNumber=94, createdTime=2019-04-19, rootId=0, userName=zlawrance, userId=f5e185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3805140054f9, moduleTitle=NEJM：Cemiplimab用于晚期皮肤鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3805140054f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1782809, encodeId=087e1e8280920, content=<a href='/topic/show?id=99c54482b2' target=_blank style='color:#2F92EE;'>#CEMIP#</a>, objectTitle=美国优先审查Sanofi，Regeneron的cemiplimab。, objectType=article, longId=136950, objectId=508213695093, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=508213695093, replyNumber=0, likeNumber=65, createdTime=2018-05-25, rootId=0, userName=zlawrance, userId=f5e185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=508213695093, moduleTitle=美国优先审查Sanofi，Regeneron的cemiplimab。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=508213695093)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CEMIP

2020-05-29

zlawrance (审核中...)

前往app查看评论内容

#CEMIP#

NEJM：Cemiplimab用于II 至 IV 期可切除的皮肤鳞状细胞癌的新辅助治疗

2023-05-02

zlawrance (审核中...)

前往app查看评论内容

#CEMIP#

研究性癌症疫苗BNT116联合Libtayo (cemiplimab) 治疗非小细胞肺癌

2022-04-08

zlawrance (审核中...)

前往app查看评论内容

#CEMIP#

NEJM：采用Cemiplimab治疗复发性宫颈癌

2022-11-11

zlawrance (审核中...)

前往app查看评论内容

#CEMIP#

Eur J Cancer：Cemiplimab治疗局部晚期/转移性皮肤鳞状细胞癌的真实数据

2022-01-02

zlawrance (审核中...)

前往app查看评论内容

#CEMIP#

Lancet oncol：Cemiplimab在局部晚期基底细胞癌中的抗肿瘤活性令人可期

2022-04-21

zlawrance (审核中...)

前往app查看评论内容

#CEMIP#

Lancet Oncol：Cemiplimab治疗局部晚期皮肤鳞状细胞癌

2020-05-18

仁心济世 (审核中...)

前往app查看评论内容

#CEMIP#

Nat cell biol:脑转移“助推剂”CEMIP，有望成为新的生物标志物

2020-02-22

zlawrance (审核中...)

前往app查看评论内容

#CEMIP#

Inovio的INO-5401联合PD-1单抗cemiplimab治疗多形胶质母细胞瘤的2期研究，显示出80％的6个月无进展生存率

2020-06-05

zlawrance (审核中...)

前往app查看评论内容

#CEMIP#

NEJM：Cemiplimab用于晚期皮肤鳞状细胞癌

2019-04-19

zlawrance (审核中...)

前往app查看评论内容

#CEMIP#

美国优先审查Sanofi，Regeneron的cemiplimab。

2018-05-25

科室
- - 订阅+
  - 更多科室
工具
服务